Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02797704|
Recruitment Status : Terminated (the treatment was found to be inefficient for all recruited patients)
First Posted : June 13, 2016
Last Update Posted : September 16, 2019
|Condition or disease||Intervention/treatment||Phase|
|Corneal Neovascularization||Drug: Aflibercept||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Subconjunctival Aflibercept on Regression of Corneal Neovascularization|
|Actual Study Start Date :||March 2, 2017|
|Actual Primary Completion Date :||September 4, 2019|
|Actual Study Completion Date :||September 10, 2019|
Experimental: SC Aflibercept
The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
Other Name: Eylea
- Regression (change from baseline) of neovascularization clinically assessed by a corneal specialist [ Time Frame: 3 months (90 days), with repeat assessment at different follow up times at 7,14,30,60 and 90 days. ]Regression of corneal neovascularization as the change from baseline will be assessed at all follow-up times on days 7,14,30,60,90 following injection by the corneal specialist, both by a clinical slit lamp exam to evaluate the area of neovascularization from the entire corneal area (which will be determined clinically by the ophthalmologist), and by performing anterior segment color photography before injection and at the last visit for comparison and documentation purposes.
- Best Corrected Visual Acuity (BCVA) [ Time Frame: 3 months ]BCVA will be assessed using a Snellen Chart at all follow-up meetings, and converted to logMAR for statistical analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02797704
|Rabin Medical Center|
|Petah Tikva, Israel|
|Principal Investigator:||Irit Bahar, MD||Head of ophthalmology department|